系统性红斑狼疮患者中羟氯喹诱导的皮肤色素沉着过度：一例报告
Hydroxychloroquine-Induced Skin Hyperpigmentation in Systemic Lupus Erythematosus Patient: A Case Report.
作者信息
Zahrani Anhar, Salaam Shaimaa, Alsifri Sahar, Alghamdi Amjad, Zamil Mohammed
机构信息
Dermatology Department, King Fahad Armed Forced Hospital, Jeddah, Saudi Arabia.
College of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
出版信息
Med Arch. 2025;79(1):67-70. doi: 10.5455/medarh.2025.79.67-70.
BACKGROUND
Hydroxychloroquine (HCQ) is an anti-malarial, antirheumatic disease-modifying medication. Besides the familiar adverse effects, HCQ has been associated with cutaneous manifestations like hyperpigmentation, vitiligo, and pruritus.
OBJECTIVE
This case report aims to describe the clinical features and outcome of hydroxychloroquine-induced skin hyperpigmentation in a patient with SLE.
CASE PRESENTATION
In this case report, we present a 32-year-old man with a history of Systemic lupus erythematosus who was treated with hydroxychloroquine. One year after treatment, the patient complained of diffused discoloration and melanonychia. Furthermore, punch biopsy from the involved sites showed pigment incontinence. To our knowledge, this is the only case reported with biopsy and photographic evidence from our geographical area.
CONCLUSION
Hydroxychloroquine-induced pigmentation is not a rare adverse effect of HCQ. Biopsy revealed pigment incontinence. Additionally, our patient had no history of ecchymoses or anticoagulant therapy.
背景
羟氯喹是一种抗疟疾、改善风湿性疾病的药物。除了常见的不良反应外，羟氯喹还与色素沉着、白癜风和瘙痒等皮肤表现有关。
目的
本病例报告旨在描述一名系统性红斑狼疮患者中羟氯喹诱导的皮肤色素沉着的临床特征和结果。
病例介绍
在本病例报告中，我们呈现了一名有系统性红斑狼疮病史的32岁男性，他接受了羟氯喹治疗。治疗一年后，患者抱怨有弥漫性变色和甲床色素沉着。此外，从受累部位进行的钻孔活检显示色素失禁。据我们所知，这是我们所在地区唯一一例有活检和照片证据报道的病例。
结论
羟氯喹诱导的色素沉着并非羟氯喹罕见的不良反应。活检显示色素失禁。此外，我们的患者没有瘀斑病史或抗凝治疗史。
Zotero 插件